Dr June Raine at the MHRA was warned about Seroxat 7 years ago

My good friend Bob Fiddaman, over at Seroxat sufferers writes:

Dr June Raine is the Director of the Post-Licensing Division at the Medicines and Healthcare Products Regulatory Agency (MHRA) and her responsibilities include all the issues that relate to medicines once they are authorised for use on the market.

Now, you have to ask yourself two fundamental questions here. Firstly, Dr June Raine is still the Director of the Post-Licensing Division at the MHRA – Why?

And secondly… Why have no criminal charges been brought against her?

Bob’s post Dr June Raine, MHRA knew 7 years ago tells the story of David Healy’s letter to her on the 7 June 2000. He wrote the day after the Court case in “Cheyenne, Wyoming… found GlaxoSmithKline guilty on several accounts including the count that Paroxetine can cause suicidality, that it specifically did so and contributed to the wrongful death of Don and Rita Schell as well as Deborah and Alyssa Tobin and that the company had been responsible for a failure to test and a failure to warn”.

David Healy wrote his letter in order to try and save lives.

As an expert witness in the Schell/Tobin case, Professor Healy had been granted access to Glaxo’s archives and had made shocking discoveries:

“What I found was that approximately 25% of the volunteers in the studies that I reviewed which were all of the healthy volunteer studies done prior to the filing of this drug for registration in the US and in the UK – 34 studies approximately in all. These yielded a 25% agitation, nervousness/akathisia rate. Some of the multiple does studies in healthy volunteers lasting 2-3 weeks yielded an up to 85% withdrawal rate in the volunteers.

All of their healthy volunteer studies were supposed to have been made available to me but not all were. Of the ones that were missing there was trace correspondence left in once indicating that the investigator had never witnessed such a level of problems in a study with healthy volunteers. Another study was a single dose study which in a dose dependent fashion yielded a 75% rate of severe adverse events most of which involved the central nervous system. There were other disturbing indications from one of the other missing studies.

Volunteers who had participated in the programme went on to suicidal acts. The relationship between their intake of paroxetine and later suicidal acts is a matter about which neither you nor SmithKline Beecham should be sanguine.

These studies were for the most part done on company employees. None of the studies bar the missing ones were done by investigators with a background in psychiatry. The investigators were general physicians with a primary interest in gastrointestinal problems who could not have been expected to detect mental problems of this sort that have concerned me and I would have thought should concern you”.

Professor Healy carried on:

“My testimony in this case also bore witness to sealed studies and other unreported data. It commented on the Montgomery Baldwin Study which yielded a projected rate of 45 suicide attempts in a group of recurrent brief depressive disordered patients on paroxetine per annum versus 12 on placebo. The figures were not statistically significant in great part one has to suggest because the company had terminated the study early. This termination and subsequent non-publication I would imagine the jury will have found and others will find significant.

Dr Hudson, currently of the MCA, was a witness for SmithKline in this case. He may well be able to give you further details on some of the issues involved. His testimony involved repeated reference to the fact that SmithKline Beecham cannot decide whether their drug had caused problems such as the wrongful death of Don and Rita Schell or Deborah and Alyssa Tobin or the wrongful deaths of many other people whose deaths have been reported to SmithKline even when these reports have been accompanied by the opinions of their treating physicians that the drug had indeed contributed to the problem. Dr Hudson’s testimony was that until controlled trials or other similar studies had proven in general that paroxetine could cause such problems that the company could not make decisions on any specific case”.

In conclusion he wrote:

“I think what will also be clear is that SmithKline Beecham recognised the presence of withdrawal syndromes in their volunteers from the early to mid 1980s. That withdrawal syndromes occurred at a much higher rate than occur on benzodiazepines. Nevertheless they applied for and have received from you and other regulators a licence to claim that their drug is effective in the prophylaxis of depression and these claims have been based on designs which almost certainly are designs better suited to show the presence of a withdrawal syndrome than designs suited to demonstrate prophylaxis in depressive disorders. A great number of people have in recent years been told that when they begin to feel ill on discontinuing treatment that this is the recrudescence of their mood disorder rather than a discontinuation syndrome from their drug. I would imagine that a great many such people and others on their behalf will feel extraordinarily let down and angry when faced with the evidence that I’ve been faced with”.

I think we all have to ask why June Raine and the MHRA did nothing in 2000 and still today they do nothing.

8 Responses to “Dr June Raine at the MHRA was warned about Seroxat 7 years ago”

  1. truthman30 Says:

    Dr Hudson, currently of the MCA, was a witness for SmithKline in this case. He may well be able to give you further details on some of the issues involved. His testimony involved repeated reference to the fact that SmithKline Beecham cannot decide whether their drug had caused problems such as the wrongful death of Don and Rita Schell or Deborah and Alyssa Tobin or the wrongful deaths of many other people whose deaths have been reported to SmithKline even when these reports have been accompanied by the opinions of their treating physicians that the drug had indeed contributed to the problem. Dr Hudson’s testimony was that until controlled trials or other similar studies had proven in general that paroxetine could cause such problems that the company could not make decisions on any specific case”.

    And now the same Dr Hudson is employed in the MHRA …
    I Wonder do they sell Ribena in the MHRA canteen…

  2. ROBERT FIDDAMAN Says:

    It’s called ‘Liebena’

    Full of vitamin C for a load of C’s

    Fid

  3. Matthew Holford Says:

    It does make one wonder what the justification was for inaction? I don’t suppose we have Dr Raine’s reply, do we?

    Matt

  4. truthman30 Says:

    There is absolutely no justifiaction for inaction…
    And there is absolutely no justification for what has happened….
    When people die as a result of corruption , deception and lies…. Justification doesn’t come into the equation….
    The MHRA and GSK are to blame for the Seroxat suicides ( of which there have been hundreds ) and for the suffering of hundreds of thousands of people who had awful side effects and withdrawals on this poisonous crap…
    Anyone who willingly participated in this gross human rights abuse should be deeply ashamed…
    Seroxat is a chemical holocaust…
    The Mental Health Thalidomide…

  5. Derek Scott Says:

    I agree Seroxat is the Mental Health Hauocaust equivalent of Thalidomide only many more people have potentially died (and will continue to die from suicide) making Seroxat an even worse threat than Thalidomide. As a consequence of the Thalidomide scandal the Government set up the impotent Committee on Safety of Medicines (See Below) which has failed countless thousands and will continue to do so unless we manage to have the system of drug regulation impartially investigated.

    http://news.bbc.co.uk/1/hi/programmes/panorama/3705268.stm

    Thalidomide was withdrawn in 1962

    But the thalidomide incident led to major changes in the way drugs were marketed and controlled in Britain.

    Less than two years after thalidomide was withdrawn from the UK market, the government had set up the Committee on Safety of Drugs (CSD), a forerunner to the current Committee for Safety in Medicines (CSM).

  6. truthman30 Says:

    And who would have thought that a thalidomide-like tragedy could happen again?…

    But it did…

    …And Seroxat is the 21 century thalidomide….

  7. seroxat secrets… The rebranding of a disease: New Statesman, 2002 « Says:

    […] of a link between suicide and SSRIs. Then, in the wake of the large damages award last June, Healy sent yet another long letter detailing his concerns, based on an analysis of the secret data. It was December before the agency […]

  8. What is GlaxoSmithKline still hiding from us - what is so important about the missing 9 pages? « seroxat secrets… Says:

    […] access to Glaxo’s archives and made shocking discoveries, so much so that on the 7 June 2000, he wrote to Dr June Raine of the UK’s Licensing body the […]


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: